| Hoffmann-La Roche Inc. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120134927 | BETA CELL MARKER ANTIBODY - The present invention relates to an antibody directed to a beta cell marker protein, in particular to an antibody directed to the protein TMEM27. | 05-31-2012 |
| 20120122120 | ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor. | 05-17-2012 |
| 20120107233 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 05-03-2012 |
| 20120095029 | IPP COMPLEX AS MARKER FOR ERLOTINIB TREATMENT - The present invention provides biomarkers which are predictive for the clinical benefit of erlotinib hydrochloride treatment in cancer patients. | 04-19-2012 |
| 20120020988 | Antibodies specifically binding to human TSLPR and methods of use - An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases. | 01-26-2012 |
| 20120020880 | Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 - This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention. | 01-26-2012 |
| 20120009680 | Cancerous Disease Modifying Antibodies - The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, inteerferons, target or reporter moieties and hematogenous cells. | 01-12-2012 |
| 20110246399 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
| 20110245103 | PREDICTING RESPONSE TO A HER INHIBITOR - The present application describes the use of low HER3 as a selection criterion for treating patients with a HER inhibitor, such as pertuzumab. | 10-06-2011 |
| 20110223159 | TUMOR THERAPY WITH AN ANTI-VEGF ANTIBODY - The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody. | 09-15-2011 |
| 20100310659 | Compositions and Uses Thereof - Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane- | 12-09-2010 |
